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Abstract: A subset of patients with celiac disease (CD) on a gluten-free diet (GFD) reported the
persistence of functional gastrointestinal disorders. Foods containing fermentable, oligosaccharides,
disaccharides, monosaccharides, and polyols (FODMAP) can trigger a broad range of gastrointestinal
symptoms in sensitive individuals. We evaluated the effects of a low FODMAP diet (LFD) on
gastrointestinal and psychological symptomatology in CD patients. A total of 50 celiac patients on
GFDs and with persistence of gastrointestinal symptoms were included. The patients were randomly
allocated to one of two dietary groups—one on a low FODMAP GFD (LF-GFD, n = 25) and the other
on a regular GFD (R-GFD, n = 25)—for 21 days. Psychological symptomatology and quality of life
were evaluated by the Symptom Checklist-90-R (SCL-90) and the Short Form (36) Health Survey
(SF-36) questionnaires, respectively. Gastrointestinal symptomatology and general well-being were
evaluated by visual analogue scale (VAS) scores. After 21 days, 21 and 23 patients completed the
dietary treatment on LF-GFD and R-GFD, respectively. A reduced global SCL-90 index (p < 0.0003)
was found in the LF-GFD group but not in the R-GFD one. However, the SF-36 scores did not differ
between groups after treatment. The VAS for abdominal pain was much lower, and the VAS for fecal
consistency enhanced after treatment in the LF-GFD group. General well-being increased in both
groups but with a much higher improvement in the LF-GFD (p = 0.03). A short-term LFD regimen
helps to improve the psychological health and gastrointestinal symptomatology with enhanced
well-being of CD patients with persisting functional gastrointestinal symptomatology. The long-term
clinical effects of LFD in particular subgroups of CD patients need further evaluation.
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1. Introduction
Celiac disease (CD) is an autoimmune multisystem disorder triggered by gluten ingestion [1,2].
CD affects genetically susceptible individuals who are known to possess the Human Leukocyte
Antigen HLA DQ2 (90%–95%) or the HLA DQ8 (5%–10%) haplotypes [3]. CD symptomatology is
mainly gastrointestinal with patients usually reporting diarrhea, bloating, abdominal pain, and weight
loss [2]. Extra-intestinal symptoms can be also frequent [4].
A gluten-free diet (GFD) is the current treatment for CD [5]. In this dietary treatment, foods
containing gluten, which is a protein found in grains, such as wheat, barley, rye, and triticale,
are excluded. Gluten induces small intestine inflammation, and a GFD helps to counteract the clinical
signs/symptoms and to prevent complications [6]. Although this treatment is highly successful,
following a strict GFD poses great difficulty to patients in their family, social, and working contexts,
thus deteriorating their quality of life [7] and causing psychological distress [8].
It is not uncommon that patients on GFDs report symptoms resembling those of irritable bowel
syndrome (IBS), which is a frequent condition in clinical practice. Reportedly, around 20–23% of treated
CD patients fulfill the Rome III criteria for IBS and also suffer from various functional gastrointestinal
symptoms, further affecting their quality of life [9]. In fact, a meta-analysis has shown that IBS-like
symptoms are common in CD patients (the pooled prevalence of IBS symptoms in treated CD patients
was 38%), concluding that higher levels of adherence to a GFD are possibly associated with some
reduction in symptomatology [10]; however, the authors also highlighted that in some patients, IBS-like
symptoms persist even after following a strict GFD.
Functional gastrointestinal disorders are characterized by recurrent or current gastrointestinal
symptoms that have no identifiable structural or biochemical basis. The most common functional
gastrointestinal disorder is IBS [11]. The variety of clinical manifestations has limited the effective
treatment of these syndromes, and most treatments to date only alleviate the primary manifestation.
A novel option for IBS treatment, which is currently generating great excitement, is the dietary regimen
with reduced amounts of fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols
(FODMAP) [12]. FODMAP are short-chain carbohydrates that are poorly absorbed in the small
intestine and increase gas production and intestinal osmolarity because of their rapid fermentation and
osmotic action [13–15]. Foods containing FODMAP can trigger gastrointestinal symptoms in sensitive
individuals [13,16].
A low FODMAP diet (LFD) appears to be associated with the reduction of IBS symptoms [17].
A very recent meta-analysis found evidence for the short-term efficacy and safety of LFD for
patients with IBS, but the long-term effects are still under investigation [18]. Recently, LFD has
been evaluated in patients with inflammatory bowel disease, showing improved symptomatology
after treatment [19]. From a clinical point of view, CD and IBS may coexist [20]. However, it is more
likely that the inflammatory process occurring in CD does not revert completely in some patients on
GFD, and similar low-grade inflammation can be present both in patients with CD and IBS [9,21].
To date there are no reports showing the potential effect of LFD on gastrointestinal symptomatology
for patients with CD; thus, we have evaluated the role of LFD on treated CD patients with the
persistence of functional gastrointestinal disorders. In addition, given the frequent manifestation of
psychopathological and behavioral abnormalities in CD patients undergoing dietary changes, their
overall psychological distress and disability were also assessed. In particular, we hypothesized that
patients being administered LFD would show improved conditions in terms of gastrointestinal and
psychopathological symptoms compared with patients on regular-GFD (R-GFD).
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2. Materials and Methods
This was a randomized double-blind intervention-controlled study, previously registered at
ClinicalTrials.gov (ref. no. IDNCT02946827). All the authors had access to the study data and reviewed
and approved the final version of the manuscript. The patients were recruited at the Center for
Prevention and Diagnosis of Celiac Disease of Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico in Milan (Italy). The University of Milan’s Institutional Review Board reviewed and
approved the study protocol according to the Helsinki Declaration, the Project Identification Code of
the Ethics Committee Approval of our study: 744_2015bis, the protocol was approved by the Ethics
Committee of Milano Area B (date 10.11.2015). All the patients gave and signed their informed consent
prior to participation in this study.
Between December 2015 and December 2017, we studied patients with CD fulfilling the
following inclusion criteria: adult age (between 18 and 60 years), treated with a GFD for at least
one year, with negative plasma tissue transglutaminase values, with IBS-like symptoms and functional
gastrointestinal disorders according to the Rome III criteria [22], and with a global well-being score
assessed by a visual analogue scale (VAS) of <4. As exclusion criteria, we considered the following:
low adherence to the GFD (as evaluated by the Celiac Dietary Adherence Test [23]), refractory CD
(as evaluated through biopsy to assess the persistence of intestinal atrophy while on a GFD and by
means of interview carried out by a trained nutritionist, who assessed patients’ adherence to the diet),
individual intolerance to disaccharides (as evaluated by hydrogen test (lactose and fructose), history
of previous nutritionist evaluation or nutritional treatment for the dietary management of IBS, taking
IBS pharmacological therapy, abdominal surgery, and type 2-diabetes.
CD was diagnosed according to positivity to the serological tests of endomysial antibodies
and tissue transglutaminase antibodies and on the basis of histological abnormalities at duodenal
biopsy according to the modified Marsh classification (following the European Society for Pediatric
Gastroenterology and Nutrition criteria) [24]. The allocation ratio was 1:1, and the recruited patients
(n = 50) were randomly allocated to either of two dietary treatments—a low FODMAP GFD (LF-GFD,
n = 25) or a R-GFD (R-GFD, n = 25)—for a time length of 21 days. Before randomization (baseline) and
at day 21, the patients underwent a physical examination, and biochemical and nutritional parameters
were assessed. After the intervention period, 21 patients in the LF-GFD and 23 in the R-GFD group
completed the protocol and were included for the analyses reported in this study. The primary outcome
was change in the VAS score for general well-being after 21 days of intervention. Secondary outcomes
were changes in the VAS score for gastrointestinal symptomatology and the Short Form (36) Health
Survey (SF-36) and the Symptom Checklist-90-R (SCL-90) scores for quality of life and psychological
symptomatology, respectively.
The sample size was calculated using G*Power v. 3.1.9.2 for Windows (Düsseldorf, Germany [25])
based on the difference in the reduction of overall IBS-like symptomatology of at least 50% after
21 days following a LFD or high-FODMAP diet in IBS patients, as reported by McIntosh et al. [26].
Considering an α-error 1% (two-tailed test) and a power of 90%, with a response of 72% after the LFD
and 21% after the high-FODMAP diet, the estimated sample size was estimated in 22 patients per
group, including an additional 20% of patients for potential losses during the follow-up. The random
allocation sequence was planned by one of the researchers (L.R.), and the participants’ enrollments
were carried out by F.B., F.F., and L.E. Both the researchers (gastroenterologists and trained nutritionists)
and the patients were blind after the assignment to each intervention group.
2.1. Clinical Evaluation
At the baseline and at the end of the intervention period, each patient underwent a clinical
and nutritional evaluation (by two gastroenterologists and two trained nutritionists). Overall health
and gastrointestinal and extra-gastrointestinal symptoms were assessed, and the gastrointestinal
symptomatology was further classified.
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2.2. Diets
The nutritional evaluation aimed at assessing anthropometrical parameters, nutritional status,
and usual dietary patterns. After clinical evaluation, a personalized GFD adjusted to match energy
and macronutrients and micronutrients daily requirements was indicated to each patient. This task
was carried out by a trained nutritionist who was only in charge of performing this task, without
involvement in patient management. In each dietary treatment, a structured 21-day dietary plan
excluding all food gluten sources was indicated. The dietary plan included structured daily meals and
specific foods/beverages and was explained in detail to each patient at the beginning of the study.
After the initial explanation, the nutritionist was available to answer any doubts or issues strictly
related to the dietary plan via e-mail or telephone. As all the patients received a structured dietary plan,
both the R-GFD, as well as the LF-GFD, received a review of their current dietary habits, in addition
to the change in FODMAP content in the LF-GFD group. The FODMAP content of the R-GFD and
LF-GFD was a median (interquartile range) of 21.8 (18.5–22.5) and 3.7 (3.0–4.12) g/day, respectively,
as previously described [27,28]. An example of the meals and foods used in both types of diets is
shown in Table 1. The group with the LF-GFD received an in-depth GFD review, food education
regarding GFD and LFD, and dietary counseling to initiate the modification of the FODMAP content
towards the LFD. The patients in the R-GFD group received an in-depth GFD review together with
food education regarding their diet. Compliance and doubts about the diet were checked 10 days later
by means of a telephone call by the same nutritionist.
Table 1. Examples of the two different prescribed diets for a typical day 1.
Meal LF-GFD(3.54 g/day FODMAP)
R-GFD
(19.9 g/day FODMAP)
Breakfast 1 cup of tea80 g of gluten free biscuits
1 glass of fresh orange juice
3 slices of gluten-free bread
3 teaspoons of honey
Morning snack 1 banana 1 apple
Lunch
130 g of gluten free pasta with zucchini
60 g of chicken
150 g of carrots
120 g of turkey thighs
200 g of cauliflowers
Afternoon snack 1 cup of blueberries 1 pear
Dinner 180 g of seafood150 g of tomatoes
200 g of asparagus soup
70 g of fresh cheese
150 g of carrots
During the day 130 g of gluten free bread6 tea spoons and half of virgin olive oil
160 g of gluten free bread
2 tea spoons of virgin olive oil
1 Dietary data represent the typical diet for a patient with an approximate energy expenditure of 1800 kcal/day.
FODMAP: Fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols; R-GFD: regular gluten-free
diet; and LF-GFD: low-FODMAP diet.
2.3. Psychological Symptoms and Quality of Life
The Symptom Checklist-90-R (SCL-90) questionnaire was used to evaluate a broad range of
psychological problems and symptomatology [29]. The scale is composed of 90 questions and assesses
the presence and severity of symptoms of mental distress regarding different symptomatic domains
(somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic
anxiety, paranoid ideation, and psychotic). Each question is awarded a score on a five-point Likert scale
with extremes from “not at all” (0 points) to “extremely” (4 points). In addition to the scores rating
specific symptoms’ intensities, a global severity index was calculated to estimate the assessment of the
patient’s psychopathological state and as an indicator of symptomatic severity and psychic distress.
Nutrients 2018, 10, 1023 5 of 14
The Short Form (36) Health Survey (SF-36) questionnaire evaluated the patients’ quality of
life. This is a 36-question-long instrument conceptually referring to eight health domains: physical
activity (10 questions), role limitations due to physical health (4 questions), role limitations due to
emotional state (3 questions), physical pain (2 questions), general health perception (5 questions),
vitality (4 questions), social activities (2 questions), mental health (5 questions), and a single question
on changes in the state of health [30]. The scores for each domain ranged between 0 and 100, where
100 represents the best possible perception of quality of life.
2.4. Gastrointestinal Symptoms
We used a series of 10-cm long visual analogue scales (VASs) referring to the level of satisfaction
with their health status and the severity of specific symptoms (abdominal pain, satisfaction with
stool consistency, bloating, postprandial fullness, early satiety, epigastric pain, and other symptoms).
A further VAS evaluated satisfaction with general well-being (0 being extremely poor satisfaction
and 10 very high satisfaction). These VASs were previously used by our group in a population with
Non Celiac Gluten Sensitivity to evaluate gastrointestinal manifestations and general well-being [31].
The magnitude of change in gastrointestinal symptoms between the baseline and at the end of the
21-day-long intervention was assessed as follows: (a) comparing each VAS score at both time points,
and (b) estimating the number of patients achieving a change in VAS score for general well-being
higher than or equal to 50% from the baseline.
2.5. Statistical Analysis
The data were described as median ± Standard Deviation (SD) or median (inter-quartile range),
depending on the parametric or non-parametric distribution of variables as assessed by graphical
inspection and the Shapiro–Wilk test. All the patients who had fully completed the intervention period,
were included in the analysis (per-protocol analysis). For SCL-90 and SF-36 scores, a within-group
comparison at both time points (the baseline and day 21) and a between-group comparison at day
21 was conducted using an independent Student’s t-test or the non-parametric Wilcoxon rank sum
test, depending on the distribution of variables. For the main outcome, the VAS score for general
well-being, with two-way Analysis of Variance (ANOVA) (factors ‘treatment’ and ‘time’) with one
repeated measure (‘time’), was used. The magnitude of change in the VAS score for the general
well-being comparison between groups at day 21 was evaluated by Fisher’s exact two-tailed test.
A 5% significance level was used, and the software packages STATA® v. 13.1 (StataCorp LLC, College
Station, TX, USA) and GraphPad Prism v. 6 (GraphPad Software, La Jolla, CA, USA) were used for
analysis and figures processing.
3. Results
3.1. Patients
The participant flow is shown in Figure A1. The patients were middle-aged, mainly women,
and within the normal weight range, according to mean body-mass index (Table 2). Regarding their
clinical symptomatology at the baseline, 64% reported the presence of IBS-like symptoms, whereas
34% reported functional symptomatology (Table 2). Among the specific symptoms, diarrhea and
constipation were the most frequently reported (34% and 32%, respectively) with lower frequencies of
mixed and non-specified gastrointestinal symptoms (12% and 8%, respectively). At the baseline the
LF-GFD and R-GFD groups were similar in relation to the presence of evaluated symptoms.
Nutrients 2018, 10, 1023 6 of 14
Table 2. Background and gastrointestinal symptoms at baseline 1.
Variable Overall(n = 50)
R-GFD
(n = 25)
LF-GFD
(n = 25) p value
†
Age, years 41.1 ± 10.1 40.4 ± 10.1 41.9 ± 10.2 0.73
Gender, female (%) 44 (88) 25 (100) 22 (3 no data) 0.09
BMI, kg/m2 22.5 ± 4.1 22.3 ± 3.6 22.1 ± 5.4 0.87
Diarrhea, n (%) 17 (34) 6 (6 no data) 11 (4 no data) 0.18
Constipation, n (%) 16 (32) 9 (7 no data) 7 (2 no data) 0.2
Mixed symptoms, n (%) 6 (12) 4 (10 no data) 2 (5 no data) 0.36
Non-specified, n (%) 4 (8) 3 (12 no data) 1 (9 no data) 0.29
Dyspepsia, n (%) 17 (34) 8 (5 no data) 9 (3 no data) 0.95
1 Data shown as mean ± Standard Deviation (SD) for continuous variables and frequency and percentage for
nominal variables. † p-value for comparison between groups using an independent t-test for continuous variables
or Chi-square or Fisher’s exact tests for nominal variables. BMI: body-mass index; R-GFD: regular gluten-free diet;
and LF-GFD: low-FODMAP gluten-free diet.
3.2. Psychological Symptoms and Quality of Life
A consistent reduction in most SCL-90 scores was found in the LF-GFD group but not in the
R-GFD group, with the global SCL-90 score being significantly reduced (p < 0.0003) compared with the
R-GFD group at day 21 (p < 0.04, Table 3, and Figure S1 in the Supplementary Materials). With respect
to specific sub-items of the SCL-90, there were no differences in the R-GFD group. However, in the
LF-GFD group some significant changes were observed between the baseline and day 21 in relation to
the majority (7 out of 9) of the psychopathological dimensions (Table 3).
Table 3. SCL-90 scores according to studied groups 1.
R-GFD LF-GFD
Baseline
(n = 25)
21-day
(n = 23)
p-Value
within
Group †
Baseline
(n = 25)
21-day
(n = 21)
p-Value
within
Group †
p-Value
between
Groups
Global index 1.61 ± 0.39 1.44 ± 0.29 0.13 ‡ 1.49 ± 0.17 1.26 ± 0.18 0.0003 0.04
Somatization 1.87 (0.71) 1.50 (0.58) 0.13 1.83 (0.62) 1.45 (0.40) 0.01 0.43
Obsessive-compulsive 1.70 (1.0) 1.60 (0.70) 0.41 1.60 (0.50) 1.30 (0.60) 0.01 0.15
Interpersonal sensitivity 1.55 (0.66) 1.38 (0.65) 0.09 1.22 (0.44) 1.11 (0.44) 0.09 0.58
Depression 1.57 (0.73) 1.50 (0.73) 0.33 1.54 (0.46) 1.38 (0.46) 0.01 0.26
Anxiety 1.30 (0.65) 1.10 (0.51) 0.17 1.30 (0.40) 1.10 (0.15) 0.02 0.60
Hostility 1.42 (0.50) 1.42 (0.58) 0.75 1.33 (0.50) 1.16 (0.08) 0.01 0.11
Phobic anxiety 1.0 (0.14) 1.0 (0.14) 0.81 1.0 (0.14) 1.0 (0.0) 0.10 0.12
Paranoid ideation 1.66 (0.83) 1.16 (0.66) 0.22 1.33 (0.50) 1.0 (0.33) 0.01 0.20
Psychotic 1.20 (0.50) 1.10 (0.25) 0.13 1.20 (0.10) 1.0 (0.10) 0.03 0.26
1 Data shown as mean± SD or median (interquartile range) for non-parametrical variables. † p-value for comparison
within groups using a non-parametric Wilcoxon rank sum test unless otherwise is indicated; ‡ independent t-test.
R-GFD: regular gluten-free diet; LF-GFD: low-FODMAP gluten-free diet.
The results of the SF-36 scores are shown in Table 4. Overall, there were no differences in the SF-36
sub-scores both within and between groups through the intervention (Table 4 and Figure S2 in the
Supplementary Materials). However, when evaluating the change percentage at day 21, a statistically
significant improvement in health perception, as well as in the physical functioning scores was found
in the LF-GFD compared with the R-GFD group (Figure 1).
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Table 4. Short Form (36) Health Survey (SF-36) subscales and global score 1.
R-GFD LF-GFD
Baseline
(n = 25)
21-day
(n = 23)
p-value within
Group †
Baseline
(n = 25)
21-day
(n = 21)
p-value within
Group †
p-value between
Groups
Health perception 46.44 ± 29.62 52.0 ± 26.93 0.53 44.54 ± 24.25 53.27 ± 18.92 0.17 0.87
Physical functioning 95.0 (15.0) 100 (30) 0.94 ‡ 95.0 (7.5) 95.0 (10.0) 0.25 0.91
Role physical 75.0 ± 34.6 81.3 ± 32.2 0.40 ‡ 79.2 ± 28.2 87.5 ± 26.4 0.18 0.65
Role emotional 69.3 ± 35.9 77.1 ± 35.9 0.41 ‡ 65.3 ± 37.4 81.8 ± 28.6 0.10 0.82
Bodily Pain 60.88 ± 23.90 64.93 ± 26.37 0.62 65.91 ± 19.29 72.77 ± 20.54 0.25 0.33
Mental health 63.91 ± 19.47 69.33 ± 14.78 0.33 62.38 ± 16.92 66.18 ± 13.89 0.40 0.51
Vitality 50.20 ± 18.14 59.66 ± 19.77 0.14 55.20 ± 14.02 57.27 ± 12.41 0.59 0.68
Social functioning 69.0 ± 22.27 78.33 ± 20.30 0.18 69.27 ± 18.78 76.13 ± 17.63 0.20 0.73
General health 53.25 ± 26.12 62.26 ± 25.28 0.29 57.47 ± 18.91 62.36 ± 17.08 0.36 0.98
1 Data shown as mean ± SD or median (interquartile range) for non-parametrical variables. † p-value for comparison within groups using an independent t-test unless otherwise is
indicated; ‡ non-parametric Wilcoxon rank sum test. R-GFD: regular gluten-free diet; LF-GFD: low-FODMAP gluten-free diet.
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3.3. Gastrointestinal Symptoms
A significant interaction was found with regard to the VAS score of abdominal pain with a
significant decrease in the LF-GFD group versus the R-GFD group at day 21 (p < 0.01, Figure 2,
and Figure S3 in the Supplementary Materials). The VAS score for satisfaction about fecal consistency
showed a tendency for a higher increase in the LF-GFD group at day 21 (p < 0.09). Post-prandial
fullness severity was lower in the LF-GFD group and decreased in both groups at day 21 (p < 0.006)
but without significant interaction (Figure 2 and Figures S4 and S5 in the Supplementary Materials).
No differences were found for non-specific functional gastrointestinal symptoms.
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groups. o ever, the improvement in well-being was greater in the LF-GFD group (p < 0.01, Figure 3).
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revealed a greater change at day 21 in the LF-GF group as co pared ith the R-GFD group (Figure 3).
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4. Discussion
To our knowledge this is the first randomized double-blind intervention-controlled study that
has investigated the effects of a LFD on patients with CD following GFDs but with persisting
functional gastrointestinal symptoms. Our results showed a positive response to LFD, an improvement
in p ychological health scores—but only limited change n quality of life—and a significant
improvement in gastrointestinal symptoms with improved perception of well-being by the patients on
the LFD.
Foods containing FODMAP can trigger IBS-like symptoms. Thes ietary c pounds can trigger
an increase in flatulence, diarrhea, and bloating that may lead to abdominal pain [13]. Our results
suggest that LFD may improve persistent gastrointestinal symptomatology in those patients who
undergo GFD and also successfully improve the psychological aspects already described in this group
of patients [32]. After our intervention, the severity of gastrointestinal symptoms, such as abdominal
pain and stool consistency, decreased when compared with the situation at the baseline and with the
R-GFD group, along with improvement in the general well-being VAS. These results are in agreement
with those reported by Halmos and colleagues, who showed that a low-FODMAP diet effectively
reduced functional gastrointestinal symptoms in patients with IBS [17]. On the other hand, a study
conducted on patients with inflammatory bowel disease has showed a positive response to LFD, thus
suggesting that a reduction in FODMAP intake offers an efficacious strategy for those patients who
present with concurrent functional gastrointestinal symptoms [33]. Although we were able to show an
effect on symptomatology as measured by VAS in the LF-GFD group, we also observed that the patients
receiving GFD reinforcement (our comparison group) did also show a decrease in symptomatology.
This issue has already been addressed in Sainsbury and co-workers, [10], who emphasized t at in-depth
dietary revision as carried out by a trained utri ionist can improve any persistent symptomatology in
CD patients. Nevertheless, our results have showed that such improvement was to a greater extent in
the LF-GFD group.
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Together with the improvements in IBS-like symptoms, we have also found that LF-GFD
can overall improve the psychopathological symptoms as measured by a well-validated
instrument. The relationship between psychological and psychiatric disturbances and CD is already
well-established, significantly influencing the reduction of the quality of life and worsening the
symptoms of affected patients [34]. The results related to the SCL-90 questionnaire have shown
post-intervention differences in the LF-GFD group but none for the patients on the R-GFD. In the
former group, in fact, we have observed a change in the vast majority of the dimensions as compared
with the baseline, suggesting that the decrease in gastrointestinal symptoms may positively influence
the improvement of a patient’s overall psychopathological burden. These results are consistent with
those reported by a previous study, in which patients with CD undertook GFDs and for whom a
post-intervention change was observed, which determined a decrease in the score for anxiety but not
for depression [32].
In another report some patients newly diagnosed with CD were evaluated in relation to the
dimensions of SCL-90 and compared with a healthy control group: the scores for somatization,
obsessive-compulsive, interpersonal sensitivity, depression, anxiety, and sleep were found to be higher
in CD patients [8]. The use of SCL-90 in a population that suffers from gastrointestinal symptoms
has been already evaluated in IBS patients, who exhibited significantly more distress compared with
other groups. In addition, the patients with gastrointestinal symptoms as a group, compared with
the healthy controls, were characterized by high levels of irritable depression and somatization [35].
From this perspective, the results from the present study, which shows a significant psychopathological
improvement in CD patients on the LF-GFD versus the R-GFD, provide an important confirmation
about the relationship between gastrointestinal and mental health in CD patients who undergo different
types of diet. In particular, to our knowledge this present study offers the first report demonstrating a
significant amelioration for CD patients of most SCL-90 items in the short-term (i.e., after 21 days) as a
result of following a LF-GFD.
The quality-of-life perception, as assessed by means of the SF-36 questionnaire, has shown only
minor differences between the studied groups: we could not establish for this group of celiac patients
any significant improvement in this regard after the LFD. This finding is in discordance with what
was previously reported. Previous data about our group of patients with non-celiac gluten sensitivity
treated with GFDs, showed an improvement in the majority of the SF-36 scores after 7 days of treatment
in a cross-over study, with both mental and physical components of the SF-36 questionnaire being
significantly lower for patients positive to a gluten challenge [31]. Other authors have shown a
quality-of-life improvement in patients with atypical and typical CD, compared with healthy controls
after a one-year-long treatment, but only with differences in two items (general health and vitality) for
subjects with typical CD [36].
Of note, even though we were not able to demonstrate any improvement in quality of life when
comparing our study groups, when the percent change was evaluated for each of the items consulted,
both health perception and physical functioning turned out higher in the LF-GFD group compared
with the R-GFD group. Therefore, we could not rule out that the aforementioned mixed results possibly
depended on the limited period of observation, with a longer follow-up period to be required in order
to better assess the changes in quality of life for CD patients following the LF-GFD.
Among the strengths of our report there is the fact that it comes from the first randomized
double-blind study performed on patients with CD and to evaluate the potential effects of a reduction
in dietary FODMAP on overall health and gastrointestinal symptomatology. As a limitation, even if
we could show significant improvement in clinical symptoms, our results were obtained only after a
short period of time (i.e., limited to three weeks) and only on patients who had fully completed the
intervention (92% and 84% in the R-GFD and LF-GFD groups, respectively).
In conclusion, our results show that nutritional intervention by a LFD can have beneficial effects
for CD patients who are on a GFD but present with persisting functional gastrointestinal disorders,
even without major changes in their quality-of-life perception. The same results also suggest that, for
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those patients with CD being treated with a GFD and experiencing IBS-like symptoms, a LFD can be
indicated by a trained nutritionist, but its beneficial effects and long-term clinical effects for this group
of selected CD patients need further investigation.
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